ArticleJournal of current ophthalmology
Impact of Two Different Antiglaucomatous Medications on Corneal Endothelium and Transparency: A Comparative Perspective.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effects of two topical antiglaucomatous agents, latanoprost and brimonidine, on corneal transparency and endothelial cell characteristics in eyes with open-angle glaucoma or ocular hypertension (OHT). Methods: This comparative cross-sectional study included 59 patients diagnosed with open-angle glaucoma or OHT, of whom 34 were on latanoprost and 25 were on brimonidine treatment. The control group consisted of 32 healthy eyes. Corneal densitometry (CD) and specular microscopy measurements were obtained, including endothelial cell density (ECD), coefficient of variation (CV), hexagonality (HEX), and central corneal thickness (CCT). Results: There was no statistically significant difference identified between the three groups with regard to ECD ( Conclusions: This is a preliminary investigation to conduct a comparative analysis of corneal clarity in patients who are under antiglaucomatous medication and in a healthy population. It can be postulated that a reduction in CD values in the latanoprost-treated group may contribute to an improvement in corneal transparency due to the remodeling effect of the drug on the cornea. It can also be inferred that the lower CCT observed in the latanoprost-treated group may be attributed to the lower CD measurements in these eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.